271 related articles for article (PubMed ID: 31704708)
1.
Stay TL; Miterko LN; Arancillo M; Lin T; Sillitoe RV
Dis Model Mech; 2019 Dec; 13(2):. PubMed ID: 31704708
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms and Consequences of Cerebellar Purkinje Cell Disinhibition in a Mouse Model of Duchenne Muscular Dystrophy.
Wu WC; Bradley SP; Christie JM; Pugh JR
J Neurosci; 2022 Mar; 42(10):2103-2115. PubMed ID: 35064002
[TBL] [Abstract][Full Text] [Related]
3. Regional and genotypic differences in intrinsic electrophysiological properties of cerebellar Purkinje neurons from wild-type and dystrophin-deficient mdx mice.
Snow WM; Anderson JE; Fry M
Neurobiol Learn Mem; 2014 Jan; 107():19-31. PubMed ID: 24220092
[TBL] [Abstract][Full Text] [Related]
4. Reduced postsynaptic GABAA receptor number and enhanced gaboxadol induced change in holding currents in Purkinje cells of the dystrophin-deficient mdx mouse.
Kueh SL; Dempster J; Head SI; Morley JW
Neurobiol Dis; 2011 Sep; 43(3):558-64. PubMed ID: 21601636
[TBL] [Abstract][Full Text] [Related]
5. Altered Synaptic Transmission and Excitability of Cerebellar Nuclear Neurons in a Mouse Model of Duchenne Muscular Dystrophy.
Kreko-Pierce T; Pugh JR
Front Cell Neurosci; 2022; 16():926518. PubMed ID: 35865113
[TBL] [Abstract][Full Text] [Related]
6. Abnormal dysbindin expression in cerebellar mossy fiber synapses in the mdx mouse model of Duchenne muscular dystrophy.
Sillitoe RV; Benson MA; Blake DJ; Hawkes R
J Neurosci; 2003 Jul; 23(16):6576-85. PubMed ID: 12878699
[TBL] [Abstract][Full Text] [Related]
7. Brain function in Duchenne muscular dystrophy.
Anderson JL; Head SI; Rae C; Morley JW
Brain; 2002 Jan; 125(Pt 1):4-13. PubMed ID: 11834588
[TBL] [Abstract][Full Text] [Related]
8. Enhanced homosynaptic LTD in cerebellar Purkinje cells of the dystrophic MDX mouse.
Anderson JL; Morley JW; Head SI
Muscle Nerve; 2010 Mar; 41(3):329-34. PubMed ID: 19722255
[TBL] [Abstract][Full Text] [Related]
9. Long-term depression is reduced in cerebellar Purkinje cells of dystrophin-deficient mdx mice.
Anderson JL; Head SI; Morley JW
Brain Res; 2004 Sep; 1019(1-2):289-92. PubMed ID: 15306266
[TBL] [Abstract][Full Text] [Related]
10. Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.
van der Pijl EM; van Putten M; Niks EH; Verschuuren JJ; Aartsma-Rus A; Plomp JJ
Eur J Neurosci; 2016 Jun; 43(12):1623-35. PubMed ID: 27037492
[TBL] [Abstract][Full Text] [Related]
11. Cognitive impairment appears progressive in the mdx mouse.
Bagdatlioglu E; Porcari P; Greally E; Blamire AM; Straub VW
Neuromuscul Disord; 2020 May; 30(5):368-388. PubMed ID: 32360405
[TBL] [Abstract][Full Text] [Related]
12. Increased density of dystrophin protein in the lateral versus the vermal mouse cerebellum.
Snow WM; Fry M; Anderson JE
Cell Mol Neurobiol; 2013 May; 33(4):513-20. PubMed ID: 23436181
[TBL] [Abstract][Full Text] [Related]
13. Duchenne muscular dystrophy: a cerebellar disorder?
Cyrulnik SE; Hinton VJ
Neurosci Biobehav Rev; 2008; 32(3):486-96. PubMed ID: 18022230
[TBL] [Abstract][Full Text] [Related]
14. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
15. Long-Term Protective Effect of Human Dystrophin Expressing Chimeric (DEC) Cell Therapy on Amelioration of Function of Cardiac, Respiratory and Skeletal Muscles in Duchenne Muscular Dystrophy.
Siemionow M; Langa P; Brodowska S; Kozlowska K; Zalants K; Budzynska K; Heydemann A
Stem Cell Rev Rep; 2022 Dec; 18(8):2872-2892. PubMed ID: 35590083
[TBL] [Abstract][Full Text] [Related]
16. Transplantation of Dystrophin Expressing Chimeric Human Cells of Myoblast/Mesenchymal Stem Cell Origin Improves Function in Duchenne Muscular Dystrophy Model.
Siemionow M; Szilagyi E; Cwykiel J; Domaszewska-Szostek A; Heydemann A; Garcia-Martinez J; Siemionow K
Stem Cells Dev; 2021 Feb; 30(4):190-202. PubMed ID: 33349121
[TBL] [Abstract][Full Text] [Related]
17. Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy.
Mitchell R; Frederick NE; Holzman ER; Agobe F; Allaway HCM; Bagher P
Am J Physiol Heart Circ Physiol; 2021 Jul; 321(1):H52-H58. PubMed ID: 34048282
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidase is hyper-active in Duchenne muscular dystrophy.
Lindsay A; McCourt PM; Karachunski P; Lowe DA; Ervasti JM
Free Radic Biol Med; 2018 Dec; 129():364-371. PubMed ID: 30312761
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological Inhibition of PKCθ Counteracts Muscle Disease in a Mouse Model of Duchenne Muscular Dystrophy.
Marrocco V; Fiore P; Benedetti A; Pisu S; Rizzuto E; Musarò A; Madaro L; Lozanoska-Ochser B; Bouché M
EBioMedicine; 2017 Feb; 16():150-161. PubMed ID: 28089792
[TBL] [Abstract][Full Text] [Related]
20. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
